| Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer (NCT05382286) | Gilead Sciences | 2022-07-25 |
| Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer (NCT05382299) | Gilead Sciences | 2022-07-20 |
| A Study of Dato-DXd in Chinese Patients With Advanced Non-Small Cell Lung Cancer, Triple-negative Breast Cancer and Other Solid Tumors (TROPION-PanTumor02) (NCT05460273) | AstraZeneca | 2022-07-11 |
| A Clinical Study of the Efficacy and Safety of Chidamide in Combination With Camrelizumab and Carboplatin or Capecitabine in the Second and Third Line Treatment of Relapsed/Metastatic Triple-negative Breast Cancer (NCT05438706) | Fudan University | 2022-07-10 |
| ARGONAUT: Stool and Blood Sample Bank for Cancer Patients (NCT04638751) | Persephone Biosciences | 2022-07-01 |
| Pre-operAtive Non-Anthracycline Chemotherapy, Durvalumab +/- RAdiation Therapy in Triple Negative Breast Cancer (NCT03872505) | Cedars-Sinai Medical Center | 2022-07-01 |
| Reverse Triple Negative Immune Resistant Breast Cancer (NCT05076682) | Fudan University | 2022-06-30 |
| A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer (NCT05451849) | TCR2 Therapeutics | 2022-06-21 |
| SKB264 Injection vs Investigator Selected Regimens to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer (NCT05347134) | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | 2022-06-10 |
| Image-based AI Predictive Biomarkers for Precision Neoadjuvant Triple-negative Breast Cancer Treatment (NCT05435352) | Ourotech, Inc. | 2022-06-06 |
| MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors (NCT05076760) | Memgen, Inc. | 2022-04-21 |
| To Evaluate Efficacy and Safety of TT-00420 (Tinengotinib) as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors (NCT05253053) | TransThera Sciences (Nanjing), Inc. | 2022-04-13 |
| Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers (NCT05296564) | Hadassah Medical Organization | 2022-04-01 |
| NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors (NCT05252390) | Nuvation Bio Inc. | 2022-03-29 |
| A Study to Investigate LYL797 in Adults With Solid Tumors (NCT05274451) | Lyell Immunopharma, Inc. | 2022-03-29 |
| Predicting Olaparib Sensitivity in Patients With Unresectable Locally Advanced/Metastatic HER2-negative Breast Cancer. (NCT05340413) | SOLTI Breast Cancer Research Group | 2022-03-25 |
| Deferoxamine Plus Chemotherapy for Metastatic Triple Negative Breast Cancer (NCT05300958) | Sun Yat-sen University | 2022-03-21 |
| Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients in Response After 6 Months of Standard IO (NCT05078047) | UNICANCER | 2022-03-08 |
| Efficacy of Talazoparib in Asian Metastatic Breast Cancer Patients With a Homologous Recombinant Deficiency (HRD) Signature (NCT05288127) | University of Malaya | 2022-03-08 |
| Trilaciclib, a CDK4/6 Inhibitor, in Patients With Early-Stage Triple Negative Breast Cancer (NCT05112536) | G1 Therapeutics, Inc. | 2022-03-03 |
| ASTEROID: A Trial of ASTX660 in Combination With Pembrolizumab (NCT05082259) | Institute of Cancer Research, United Kingdom | 2022-03-02 |
| A Safety and Preliminary Efficacy Study of SBT6290 Alone and in Combination With PD-(L)1 Inhibitors in Select Advanced Solid Tumors (NCT05234606) | Silverback Therapeutics | 2022-03-01 |
| A Study of HMBD-002, a Monoclonal Antibody Targeting VISTA, as Monotherapy and Combined With Pembrolizumab, in Patients With Advanced Solid Tumors (NCT05082610) | Hummingbird Bioscience | 2022-02-28 |
| First in Human Phase 1 Study of AG01 Anti-Progranulin/GP88 Antibody in Advanced Solid Tumor Malignancies (NCT05627960) | A&G Pharmaceutical Inc. | 2022-02-14 |
| A Study of Camrelizumab in Combination With Chemotherapy Regimen Comparative Chemotherapy Regimen for Metastatic Triple-negative Breast Cancer (NCT05134194) | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 2022-01-17 |
| Albumin-Bound Paclitaxel Combined With Antiangiogenic Agents in First-line Treatment of Relapsed or Metastatic TNBC (NCT05192798) | The First Affiliated Hospital of Bengbu Medical University | 2022-01-14 |
| Neoadjuvant Toripalimab Plus Docetaxel and Carboplatin in Patients With Localized TNBC (NeoTOP) (NCT06618014) | Sun Yat-sen University | 2022-01-11 |
| Radiotherapy in Combo With Chemo and Immunotherapy in Patients With PD-L1 Positive Metastatic TNBC (NCT05233696) | University of Colorado, Denver | 2022-01-04 |
| Programmed Death-Ligand1 Expression in Her-2 Positive and Triple Negative Breast Cancer (NCT05169853) | Ain Shams University | 2022-01-01 |
| Study to Evaluate Safety and Efficacy of TJ107 Combine With PD-1 in Patients With Solid Tumors (NCT05145907) | TJ Biopharma Co., Ltd. | 2021-12-22 |
| Study of Screening Brain MRIs in Stage IV Breast Cancer (NCT05115474) | H. Lee Moffitt Cancer Center and Research Institute | 2021-12-21 |
| Study of Magrolimab Combination Therapy in Patients With Non-Surgically Removable Locally Advanced or Metastatic Triple-Negative Breast Cancer (NCT04958785) | Gilead Sciences | 2021-12-14 |
| Trilaciclib in Patients Receiving Sacituzumab Govitecan-hziy for Triple Negative Breast Cancer (NCT05113966) | G1 Therapeutics, Inc. | 2021-12-08 |
| Molecular Subtyping of Triple-negative Breast Cancer and African Ancestry-related Immunogenicity (NCT05111067) | Nova Scotia Health Authority | 2021-12-01 |
| A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With Advanced Cancer Or Metastatic Cancer (NCT04916002) | Regeneron Pharmaceuticals | 2021-11-30 |
| MicroRNA Profiles in Triple Negative Breast Cancer (NCT04771871) | University College Hospital, Ibadan | 2021-11-29 |
| The Gut Microbiome and Immune Checkpoint Inhibitor Therapy in Solid Tumors (NCT05037825) | VastBiome | 2021-11-22 |
| A Phase I/IIa Trial of HMBD-001 in Advanced HER3 Positive Solid Tumours (NCT05057013) | Cancer Research UK | 2021-11-10 |
| A Phase II Study of Chiauranib in Combine With Capecitabine in TNBC (NCT05336721) | Chipscreen Biosciences, Ltd. | 2021-11-05 |
| Asian Multicenter Prospective Study of ctDNA Sequencing (NCT05099978) | National Cancer Center, Japan | 2021-11-01 |
| Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan (NCT05005403) | AbbVie | 2021-11-01 |
| Capecitabine as Maintenance Therapy vs Observation in Early-stage Triple-negative Breast Cancer (NCT07143097) | Beni-Suef University | 2021-11-01 |
| Impact of Vitamin D Supplementation on the Rate of Pathologic Complete Response in Vitamin D Deficient Patients (NCT04677816) | Wake Forest University Health Sciences | 2021-10-22 |
| A Study to Evaluate TAlazoparib, Radiotherapy and Atezolizumab in gBRCA 1/2 Negative Patients With PD-L1+ Metastatic Triple Negative Breast Cancer (NCT04690855) | Mylin A. Torres, MD | 2021-10-04 |
| A Study to Evaluate the Efficacy and Safety of SG001 in Combination With Nab-Paclitaxel in Patients With Advanced Triple-Negative Breast Cancer (TNBC) (NCT05068141) | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 2021-10-01 |
| Sitravatinib in Metastatic Breast Cancer (NCT04123704) | Xiang Zhang | 2021-09-22 |
| Imaging Performance Assessment of 89Zi-girentuximab (89Zr-TLX250) PET in Metastatic Triple Negative Breast Cancer (NCT04758780) | Institut Cancerologie de l'Ouest | 2021-09-21 |
| A Beta-only IL-2 ImmunoTherapY Study (NCT05086692) | Medicenna Therapeutics, Inc. | 2021-08-27 |
| A Study of Fruquintinib in Combination With Tislelizumab in Advanced Solid Tumors (NCT04577963) | Hutchmed | 2021-08-09 |
| Multiparametric MRI as a Non-Invasive Biomarker of the Tumor Microenviroment (NCT04803084) | Laura Kennedy | 2021-08-09 |
| Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067 (NCT04787042) | Simcha IL-18, Inc. | 2021-08-06 |
| ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer (NCT04602117) | QuantumLeap Healthcare Collaborative | 2021-07-28 |
| A Study to Assess the Safety, Tolerability and Antitumor Activity of X4P-001 in Combination With TNBC (NCT05103917) | Abbisko Therapeutics Co, Ltd | 2021-07-21 |
| Effect of Huaier Granule on Adjuvant Treatment for High-risk Early-stage Triple-negative Breast Cancer (NCT04790305) | Fudan University | 2021-06-18 |
| Study of Camrelizumab Plus Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (NCT04907344) | Tianjin Medical University Cancer Institute and Hospital | 2021-06-15 |
| Study of XB002 in Subjects With Solid Tumors (JEWEL-101) (NCT04925284) | Exelixis | 2021-06-07 |
| Maintenance Treatment With Eribulin Mesylate Versus Observation in Triple Negative Breast Cancer Patients (NCT04502680) | The First Affiliated Hospital with Nanjing Medical University | 2021-06-01 |
| Tislelizumab in Combination With Eribulin for Patients With Metastatic Previously heaviLy-treAted TriplE-negative Breast Cancer：A Prospective Multiple-center Phase II Study (NCT04913571) | Fudan University | 2021-05-27 |
| Docetaxel Chemotherapy and Pembrolizumab Plus Interleukin-12 Gene Therapy in Triple Negative Breast Cancer (NCT04095689) | The Methodist Hospital Research Institute | 2021-05-12 |
| BN-Brachyury, Entinostat, Adotrastuzumab Emtansine and M7824 in Advanced Stage Breast Cancer (BrEAsT) (NCT04296942) | National Cancer Institute (NCI) | 2021-05-04 |
| Exosome as the Prognostic and Predictive Biomarker in EBC Patients (NCT05955521) | Samsung Medical Center | 2021-05-01 |
| A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive/Her2 Negative Breast Cancer (NCT04683679) | Memorial Sloan Kettering Cancer Center | 2021-04-21 |
| Standard Chemotherapy Plus Moxifloxacin as First-line Treatment for Metastatic Triple-negative Breast Cancer (NCT04722978) | Sun Yat-Sen University Cancer Center | 2021-04-20 |
| CMP-001 and Pre-operative Stereotactic Body Radiation Therapy (SBRT) in Early Stage Triple Negative Breast Cancer (TNBC) (NCT04807192) | Centre Hospitalier Universitaire Vaudois | 2021-04-07 |
| Atezolizumab Combined With BDB001 AnD Immunogenic Radiotherapy in Patients With Advanced Solid Tumors (NCT03915678) | Institut Bergonié | 2021-03-31 |
| Study of TT-00420 (Tinengotinib) Tablet as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors (NCT04742959) | TransThera Sciences (Nanjing), Inc. | 2021-03-14 |
| PD-1 Inhibitor Concurrent With Chemotherapy as Neoadjuvant Therapy for TNBC (NCT04809779) | First Affiliated Hospital, Sun Yat-Sen University | 2021-03-01 |
| Study to Compare a Mono Atezolizumab Window Followed by a Atezolizumab - CTX Therapy With Atezolizumab - CTX Therapy (NCT04770272) | Palleos Healthcare GmbH | 2021-03-01 |
| Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers (NCT04464967) | NKGen Biotech, Inc. | 2021-03-01 |
| A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in Metastatic or Advanced Solid Tumors (NCT04725331) | Transgene | 2021-02-25 |
| Study of XL102 as Single-Agent and Combination Therapy in Subjects With Solid Tumors (QUARTZ-101) (NCT04726332) | Exelixis | 2021-02-10 |
| INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors (NCT04580485) | Incyte Corporation | 2021-02-03 |
| Serial Circulating Tumor DNA (ctDNA) Monitoring During Adjuvant Capecitabine in Early Triple-negative Breast Cancer (NCT04768426) | Stanford University | 2021-02-03 |
| Communicating With Patients on Cancer Resistance to Treatment: the Development of a Communication Tool. (HECTOR) (NCT04118062) | Institut Curie | 2021-02-02 |
| Guided Treatment Based on Mini-PDX in Metastatic Triple Negative Breast Cancer (NCT04745975) | Fudan University | 2021-02-01 |
| Stromal Tumor-Infiltrating Lymphocyte Levels Are Associated With Immune Checkpoint Proteins In Triple Negative Breast Cancer Patients Receiving Neoadjuvant Chemotherapy (NCT06965361) | Ziauddin University | 2021-01-02 |
| Pre-op Pembro + Radiation Therapy in Breast Cancer (P-RAD) (NCT04443348) | Laura M. Spring, MD | 2020-12-16 |
| A Study of Camrelizumab Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (NCT04613674) | Jiangsu HengRui Medicine Co., Ltd. | 2020-12-09 |
| Evaluation of a Plasma Protein Profile as a Predictive Biomarker for Metastatic Relapse in Triple Negative Breast Cancer Patients (NCT04438681) | Centre Jean Perrin | 2020-11-27 |
| Neoadjuvant Nivolumab and Chemotherapy in Patients With Localized Triple-negative Breast Cancer (NCT04331067) | Washington University School of Medicine | 2020-11-19 |
| Palbociclib and Binimetinib in Advanced Triple Negative Breast Cancer (NCT04494958) | Fundacion Oncosur | 2020-11-18 |
| CT-based Radiomics of ALN pCR (ypN0) in Breast Cancer Undergoing NAC (NCT04457700) | Peking University | 2020-11-01 |
| Neoadjuvant Treatment of Early Triple-negative Breast Cancer With Chidamide and Chemotherapy (NCT04582955) | Tianjin Medical University Cancer Institute and Hospital | 2020-10-30 |
| The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (NCT04585750) | PMV Pharmaceuticals, Inc | 2020-10-29 |
| A Study of PY314 in Subjects With Advanced Solid Tumors (NCT04691375) | Ikena Oncology | 2020-10-29 |
| Sacituzumab Govitecan in Primary HER2-negative Breast Cancer (NCT04595565) | GBG Forschungs GmbH | 2020-10-28 |
| Ipatasertib Plus Non-Taxane Chemotherapy for Advanced or Metastatic Triple-Negative Breast Cancer (NCT04464174) | MedSIR | 2020-10-08 |
| A Study of Zilovertamab Vedotin (MK-2140/VLS-101) in Participants With Solid Tumors (MK-2140-002) (NCT04504916) | VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 2020-10-07 |
| First Line Atezolizumab, Paclitaxel, and Bevacizumab (Avastin®) in mTNBC (NCT04408118) | MedSIR | 2020-10-05 |
| A Study of the Safety, Efficacy, and Pharmacokinetics of Tiragolumab in Combination With Atezolizumab and Chemotherapy in Participants With Triple-Negative Breast Cancer (NCT04584112) | Hoffmann-La Roche | 2020-09-28 |
| A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers (NCT04260802) | Ocellaris Pharma, Inc. | 2020-09-24 |
| Oral Etoposide Combined With Anlotinib in Advanced Triple Negative Breast Cancer (NCT04452370) | Chinese Academy of Medical Sciences | 2020-09-23 |
| AN0025 and Pembrolizumab Combination in Advanced Solid Tumors (NCT04432857) | Adlai Nortye Biopharma Co., Ltd. | 2020-08-20 |
| A Study of NM21-1480 in Adult Patients With Advanced Solid Tumors (NCT04442126) | Numab Therapeutics AG | 2020-08-19 |
| PAveMenT: Palbociclib and Avelumab in Metastatic AR+ Triple Negative Breast Cancer (NCT04360941) | Royal Marsden NHS Foundation Trust | 2020-08-11 |
| A Prospective, Phase II Trial Using ctDNA to Initiate Post-operation Boost Therapy After NAC in TNBC (NCT04501523) | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 2020-08-03 |
| Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC (NCT04468061) | Dana-Farber Cancer Institute | 2020-07-20 |
| A Study of the Efficacy and Safety of Camrelizumab Plus Radiotherapy for Patients With Early Triple-Negative Breast (NCT04481763) | Jiangxi Provincial Cancer Hospital | 2020-07-14 |
| A Phase 3 Study Comparing Carelizumab Plus Nab-paclitaxel and Apatinib, Carelizumab Plus Nab-paclitaxel, and Nab-paclitaxel in Patients With Advanced Triple Negative Breast Cancer. (NCT04335006) | Jiangsu HengRui Medicine Co., Ltd. | 2020-07-14 |
| Sacituzumab Govitecan In TNBC (NCT04230109) | Massachusetts General Hospital | 2020-07-14 |